PARIS, Nov. 30, 2007 (Thomson Financial delivered by Newstex) -- Sanofi-Aventis (NYSE:SNY) is prepared to make acquisitions or partnerships with biotech companies as it aims to double or triple by 2012 the proportion of drugs it produces using biotechnology, research chief Marc Cluzel said.
